Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global viral filtration market was valued at US$ 4.29 billion in 2021 and is expected to register a revenue CAGR of 10% to reach US$ 10.11 billion by 2030.

Market Fundamental 

Viral filtration uses a membrane barrier to keep virus particles in place and provides a crucial line of defense against unforeseen viruses. The safety of biopharmaceutical medicinal products will greatly depend on pharmaceutical corporations' increased spending on virus filtration. 

[87624824]

Market Dynamic 

The adoption of single-use technologies, increase in viral contamination of treatments, rise in R&D spending, and government backing are the factors propelling the global virus filtration market revenue. However, a highly consolidated market and strict laws governing the validation of filtering products limit market revenue expansion. Outsourcing in the pharmaceutical industry and developing nations is the sign of potential growth for this market revenue. Additionally, the market revenue is expanding because of factors, including the rising prevalence of chronic diseases. The market for biologics is expected to increase due to the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. Market players expect North America and Europe to grow and account for the largest market revenue share as they invest in cutting-edge technologies.

Market Ecosystem 

The global viral filtration market has been analyzed from four perspectives product, technology, application, and region.

Viral Filtration Market Product

Based on product, the global viral filtration market has been segmented into consumables, instruments, and services. The consumable segment is sub-segmented into kits and reagents and others, whereas the instrument segment is sub-segmented into the filtration system and chromatography system. 

The consumable segment dominates the global market during the forecast period due to the utilization of these products for viral filtration. Consumables such as reagents, kits, and membranes are likely to increase in demand as more attention is paid to developing vaccines, protein treatments, blood products, cellular therapy products, gene therapy products, tissue products, and stem cell products.

Viral Filtration Market Technology

Based on product, the global viral filtration market has been segmented into filtration and chromatography. 

The filtration segment dominates the global market with the largest revenue share during the forecast period due to the increased use of these goods in research, medical device manufacturing, and the production of biologics. Additionally, it offers a number of benefits, such as saving the proteins from the denaturation process in the product or sample and excellent efficacy and purity in both  small and large-scale operations.

Viral Filtration Market Application

[2413123]

Based on application, the global viral filtration market has been segmented into biologicals, stem cell products, medical devices, water purification, and air purification. The biologicals are sub-segmented into vaccine and therapeutics, blood and blood products, cellular and gene therapy products, and tissue & tissue products.

The biological segment dominates the global market during the forecast period. This significant market revenue share can be because of the rising incidence of chronic diseases that increases the demand for biologics, such as growth hormone deficiency, blood disorders, cancer, diabetes, and autoimmune disorders.

Viral Filtration Market End-User 

Based on end-user, the global viral filtration market has been segmented into biopharmaceuticals and biotechnology, contract research organization, medical devices company, and academic institutes and research laboratories. 

The biopharmaceuticals and biotechnology segment dominates the global market during the forecast period due to rising R&D efforts, biologics output, and expansion of the biopharmaceutical industry. Additionally, in the United States, Germany, the United Kingdom, Japan, China, and India, viral filtration technology is widely used. Having large biopharmaceutical and biotechnology companies nearby, having a strong healthcare system, and having access to cutting-edge products are some of the main drivers for revenue growth in these nations. 

Viral Filtration Market Region

Based on product, the global viral filtration market has been segmented into North America, Europe, Asia Pacific, and the rest of the World. 

North America accounts for the largest revenue share in the global market, and this dominance is expected to continue during the forecast period. The established biotechnology and biopharmaceutical sectors in the United States have increased the region's demand for improved viral clearance products for research and development and biologics manufacturing. 

Due to the increasing demand for novel virus filtration products for research and the development and manufacturing of biologics, Europe accounts for the second-largest market revenue share. The regional market revenue is expected to be driven by the highly developed healthcare infrastructure and significant investments in R&D, particularly in Germany, the United Kingdom, and France.

During the forecast period, Asia Pacific is expected to register the highest revenue CAGR due to an increase in the number of trauma cases and traffic accidents. According to estimates, the regional revenue growth is fueled by untapped growth prospects in the quickly expanding Asian economies of China, India, and Indonesia.

Competitive Landscape 

The prominent market players in the global viral filtrations market are:

• Merck KGaA
• Asahi Kasei Corporation
• BioProcess International
• Sartorius AG
• General Electric
• Thermo Fisher Scientific, Inc.
• General Electric Company
• PendoTECH
• Lonza
• Charles River Laboratories
• Sotera Health
• WuXi AppTec. 

Strategic Development 

• In January 2021, With Charles River Laboratories, one of the world's top providers of laboratory services, SenzaGen renewed and expanded its global collaboration arrangement with this business. The agreement was expanded to encompass all tests available in the GARD portfolio to fulfill the rising demand for risk assessment of chemicals utilizing SenzaGen's non-animal test platform GARD.
• In June 2021, Lonza announced its partnership with Moderna, a biotechnology firm that developed the first messenger RNA vaccines and medicines. The extended agreement will allow for more COVID-19 Vaccine Moderna medicinal substance manufacturing. At Lonza's Geleen facility, a new manufacturing line for synthesizing drug substances will be made available.
• In October 2019, Asahi Kasei Medical acquired ViruSure. The acquisition was carried out by Asahi Kasei Medical as part of the organizational growth and reinforcement strategy. The objective was to further strengthen the company's bioprocess business, which is focused on PlanovaTM virus removal filters, by utilizing ViruSure's cell banking services and biosafety testing services.

Frequently Asked Questions About This Report